-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46

Benzinga·08/10/2026 15:07:47
Listen to the news
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.